The oral semaglutide (tablet) formulation represents a particularly compelling growth vector, as patient preference surveys consistently demonstrate that 60% to 70% of patients would prefer an oral GLP-1 therapy over injectable alternatives, and the global pipeline of oral GLP-1 formulations in development by companies including AstraZeneca, Pfizer, and Eli Lilly will require large volumes of high-purity API meeting oral bioavailability specifications
& Lindenberg, S
For anyone ready to act on their health now, an approved, medically supervised option is the responsible path and its one we can start with you
Neurol Sci 42 , 31453166 (2021)
TRIPLE G is a synthetic peptide belonging to the class of triple agonists, designed to simultaneously activate three receptors: GIP-R (glucose-dependent insulinotropic polypeptide receptor), GLP-1R (glucagon-like peptide-1 receptor) and GCGR (glucagon receptor)
NO ES UN MEDICAMENTO Y NO SUPLE UNA ALIMENTACIN EQUILIBRADA